Showing results (1951-1960 of 1,996) with videos related to

Sort By:
Pageof 200
The Lancet. Neurology|October 20, 2023
Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trialAnna Kopczak, Michael S Stringer, Hilde van den Brink, et al.
The Lancet. Neurology|April 13, 2024
RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analysesEmil K Gustavsson, Jordan Follett, Joanne Trinh, et al.
The Lancet. Neurology|September 17, 2023
Migraine in older adultsSarah Sonja Hugger, Thien Phu Do, Håkan Ashina, et al.
The Lancet. Neurology|August 18, 2023
The assessment of dysphagia after stroke: state of the art and future directionsBendix Labeit, Emilia Michou, Shaheen Hamdy, et al.
The Lancet. Neurology|January 24, 2024
Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysisMarianne Chapleau, Renaud La Joie, Keir Yong, et al.
The Lancet. Neurology|January 24, 2024
Challenges and opportunities in spinal muscular atrophy therapeuticsCrystal J J Yeo, Eduardo F Tizzano, Basil T Darras
The Lancet. Neurology|December 15, 2023
Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trialMukul Sharma, Carlos A Molina, Kazunori Toyoda, et al.
The Lancet. Neurology|December 15, 2023
Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension studyAngela Schulz, Nicola Specchio, Emily de Los Reyes, et al.
The Lancet. Neurology|February 16, 2024
Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trialCristina Tassorelli, Krisztián Nagy, Patricia Pozo-Rosich, et al.
The Lancet. Neurology|January 27, 2024
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 studyRalf Reilmann, Karen E Anderson, Andrew Feigin, et al.
Pageof 200